ArticleJournal of thoracic disease2025
Initial experience of intrathoracic rib fixation using RibFix Advantage™ at a major trauma centre: operative technique and case series.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple rib fractures are the most frequently encountered traumatic chest injury. Randomised control trials have shown superiority of surgical stabilisation of rib fractures (SSRF) for reduction of displaced fractures in comparison to non-operative management. As SSRF techniques continue to evolve, new technologies have enabled less invasive approaches, including intrathoracic rib fixation, which can achieve chest wall stability while allowing for a less invasive approach. This article reports our initial experience with intrathoracic SSRF (I-SSRF), our operative technique, case series description, and learning points when implementing this technique. We present our operative technique alongside a single-centre, prospective case series, representing the first reported European experience with intrathoracic SSRF using the RibFix Advantage™ system. This includes the first fifteen patients with multiple rib fractures who were treated with SSRF using an intrathoracic fixation system from May 2025 to August 2025 at our major trauma centre in the United Kingdom. The majority of these patients sustained associated intrathoracic injuries requiring intervention, including haemothorax, lung lacerations, and 20% with diaphragmatic defects. The average length of stay for patients subjected to I-SSRF was 5 days (range, 3-9 days). The only reported complication was with one patient treated for wound infection with antibiotics. This early experience has highlighted a safe and effective implementation of this technique at a major trauma centre. This technique of I-SSRF in chest trauma offers benefits such as thoracoscopic assessment and repair of other intrathoracic injuries, less invasive incisions for access, and a short length of hospital stay with good pain relief for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.